Evidence map›Paper›PMID 40833639›Full record

ArticleMikrochimica acta2025

Simultaneous EGFR mutation detection using a sensitive dual-target biosensor based on 3D hollow carbon nanosphere synergy with circular bipedal DNA walkers.

Linxin He, Yuxin Wei, Cizhi Chen, Chuanhai Li, Ying Xu, Mei Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Linxin HeClinical Laboratory, Clinical Medical College and, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, P.R. China.
Yuxin WeiClinical Laboratory, Clinical Medical College and, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, P.R. China.
Cizhi ChenClinical Laboratory, Clinical Medical College and, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, P.R. China.
Chuanhai LiKey Laboratory of Target Discovery and Protein Drug Development in Major Diseases of Sichuan Higher Education Institutes, School of Bioscience and Technology, Chengdu Medical College, Chengdu, 610500, PR China.
Ying XuClinical Laboratory, Clinical Medical College and, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, P.R. China. xuying1977121@163.com.
Mei ChenClinical Laboratory, Clinical Medical College and, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, P.R. China. 396762073@qq.com.

Funding

CMC Excellent-talent Program 2024yxGzn08Project of Central Guiding Local Scientific and Technological Development in Sichuan 2024ZYD0027the Science and Technology Project of Chengdu 2024-YF05-02568-SN
6 · The paper itself

Abstract

A sensitive dual-target electrochemical biosensor was developed integrating circular bipedal DNA walkers with a three-dimensional hollow carbon nanospheres-tetrametallic nanoparticle (3D HCNs-TT NPs) modified platform, enabling concurrent detection of two critical epidermal growth factor receptor (EGFR) exon 19 mutations: E746_A750 deletion (Mut DNA A) and L747_S752delinsS (Mut DNA B). The circular bipedal DNA walkers address the limitations of low amplification efficiency in traditional single-legged DNA walkers and mitigate the sensitivity reduction caused by excessively long walking strands. Additionally, we used the 3D HCNs-TT NPs nanocomposite materials to modify the electrodes, which significantly increased the electron transfer rate and provided more active sites for molecular probe loading, thereby further enhancing the performance of the detection platform. This biosensor demonstrated good performance, with detection limits as low as 3.4 fM (Mut DNA A) and 2 fM (Mut DNA B) (S/N = 3). The designed sensor was applied for detection using clinical samples, including cells with gene mutations and diluted human serum, and these results confirm the sensor's potential for clinical translation, offering a potential tool for early non-small cell lung cancer (NSCLC) diagnosis and personalized tyrosine kinase inhibitors (TKI) therapy guidance.

Indexed as

Biosensing TechniquesDNAErbB ReceptorsNanospheresCarbonElectrochemical TechniquesHumansLimit of DetectionMetal NanoparticlesMutationCarbonDNAEGFR protein, humanErbB ReceptorsCircular bipedal DNA walkerEGFRHCNs-TT NPsMultiplex detectionNSCLC

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.